The combination of cabozantinib (VEGF-targeted treatment) and nivolumab (checkpoint inhibitor) efficiently turns locally progressed HCC to resectable disease while also inducing a robust immune response [71]. Here, VEGFA is linked to hepatocellular carcinoma.